Zotatifin

• CAT Number: I015420
• CAS Number: 2098191-53-6
• Molecular Formula: C₂₈H₂₉N₃O₅
• Molecular Weight: 487.55
• Purity: ≥95%
• IUPAC Name: 4-[(2S,3R,4S,5S,6R)-4-[(dimethylamino)methyl]-2,3-dihydroxy-10,12-dimethoxy-5-phenyl-7-oxa-11-azatricyclo[6.4.0.02,6]dodeca-1(12),8,10-trien-6-yl]benzonitrile
• InChI: InChI=1S/C28H29N3O5/c1-31(2)16-20-23(18-8-6-5-7-9-18)28(19-12-10-17(15-29)11-13-19)27(33,25(20)32)24-21(36-28)14-22(34-3)30-26(24)35-4/h5-14,20,23,25,32-33H,16H2,1-4H3/t20-,23-,25-,27+,28+/m1/s1
• InChIKey: QYCXWOACFWMQFO-WZWZCULESA-N
• SMILES: CN(C)CC1C(C2(C(C1O)(C3=C(N=C(C=C3O2)OC)OC)O)C4=CC=C(C=C4)C#N)C5=CC=CC=C5

Zotatifin (Cat No.:I015420) is a selective inhibitor of eIF4A, an RNA helicase involved in mRNA translation initiation. By targeting eIF4A, Zotatifin disrupts the translation of oncogenic mRNAs, leading to the inhibition of cancer cell growth and survival. It exhibits potential as an anti-cancer agent in preclinical studies, offering promise for therapeutic applications against various types of cancer.

Reference

[1]. Peggy A. Thompson, et al. Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-tumor Activity in B-cell Malignancies.[2]. Gordon DE, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature. 2020 Apr 30.